ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - valsartan - טבליות מצופות פילם - valsartan 40 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - valsartan - טבליות מצופות פילם - valsartan 80 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - valsartan - טבליות מצופות פילם - valsartan 160 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - candesartan cilexetil; hydrochlorothiazide - טבליה - candesartan cilexetil 16 mg; hydrochlorothiazide 12.5 mg - candesartan and diuretics - candesartan and diuretics - essential hypertension, where monotherapy with candesartan cilexetil or hydrochlorothiazide is not sufficient.

ישראל - עברית - Ministry of Health

cts chemical industries ltd, israel - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: losartan indicated for the treatment of heart failure ( nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate.switching patients with heart failure who are stable on an ace inhibitor to losartan is not recommended. renal protection in type - 2 diabetic patients with proteinuria: losartan indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease ( need for dialysis or renal transplantation) or death and to reduce proteinuria.reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrphy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of losartan on the primary composite end point

ישראל - עברית - Ministry of Health

cts chemical industries ltd, israel - losartan potassium - טבליה - losartan potassium 12.5 mg - losartan - losartan - hypertension : losartan is indicated for the treatment of hypertension. heart failure: losartan is indicated for the treatment of heart failure (nyha ii) when treatment with an ace inhibitor is no longer considered appropriate. switching patients with heart failure who are stable on an ace inhibitor to losartan is not recommended.

ישראל - עברית - Ministry of Health

unipharm ltd, israel - valsartan - טבליה - valsartan 160 mg - valsartan - valsartan - for treatment of hypertension. valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalizations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - candesartan cilexetil - טבליה - candesartan cilexetil 4 mg - candesartan - candesartan - hypertension. treatment of patients with heart failure and impaired left ventricle systolic function ( left ventricular ejection fraction < or = 40 % ) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - candesartan cilexetil - טבליה - candesartan cilexetil 8 mg - candesartan - candesartan - hypertension. treatment of patients with heart failure and impaired left ventricle systolic function ( left ventricular ejection fraction < or = 40 % ) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - candesartan cilexetil - טבליה - candesartan cilexetil 16 mg - candesartan - candesartan - hypertension. treatment of patients with heart failure and impaired left ventricle systolic function ( left ventricular ejection fraction < or = 40 % ) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.